AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER
Latest Information Update: 24 Feb 2026
At a glance
- Drugs 707 3SBio (Primary) ; Enfortumab vedotin (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
Most Recent Events
- 24 Feb 2026 New trial record